Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBCG-SIC
- Development stage
- Preclinical
- Lead developer
- Chung-Ang University Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
rBCG-SIC is a genetically modified recombinant Bacillus Calmette-Guérin (rBCG) strain engineered to express the streptococcal inhibitor of complement (sic) gene. Developed by researchers in South Korea, including those at Chung-Ang University Hospital, Hanil General Hospital, and VHS Medical Center, this immunotherapeutic agent is designed to overcome BCG unresponsiveness in non-muscle invasive bladder cancer (NMIBC). By expressing the sic gene, the recombinant bacterium exhibits enhanced resistance to host-derived antimicrobial peptides (such as cathelicidin and alpha-defensin-1) and demonstrates improved internalization into bladder cancer cells. This leads to increased secretion of pro-inflammatory cytokines (such as interleukin-6) and enhanced antitumor immune responses, resulting in reduced tumor volume in preclinical models.
- Other names
- recombinant Bacillus Calmette-Guerin containing sic generecombinant Bacillus Calmette-Guerin containing the streptococcal inhibitor of the complement generecombinant Bacillus Calmette-Guérin containing sic generecombinant Bacillus Calmette-Guérin containing the streptococcal inhibitor of the complement gene
02
Targets
CAMP (Cathelicidin antimicrobial peptide)
Beyond the preview
Go deeper on rBCG-SIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBCG-SIC.